EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Redx Pharma received two takeover offers. Having bought a 46% stake in Redx, thereby triggering a requirement to make a cash offer for the remaining shares, Redmile looks to be in the box seat. Release I More

> A phase 2b trial of UCB’s padsevonil in refractory epilepsy missed its primary endpoints. Analysts at Jefferies think the drug may be discontinued. Statement

> Medicxi appointed Sandy Zweifach and Paul Sekhri as venture partners. Release 

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

> The FDA scrapped plans to discuss DBV Technologies’ peanut allergy drug at an advisory committee in May after identifying “questions regarding efficacy, including the impact of patch-site adhesion.” DBV warned the submission of data to resolve the questions may constitute a major amendment that delays a decision on whether to approve the product. Statement 

> Synairgen secured clearance to start testing its inhaled formulation of interferon-beta-1a in COVID-19 patients. The phase 2 trial will enroll 100 patients in the U.K. Release  

> Horama licensed the global rights to a gene therapy for inherited retinal dystrophies. A phase 1/2 is due to start in 2023. Statement 

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.